Kornimate/medical-research-clean huggingface dataset:
digital dyadic empowerment program on lifestyle modification for chronic kidney disease management

Conditions: Chronic Kidney Diseases

Summary: the goal of this clinical trial is to find out if the digital dyadic empowerment program (ddep) can help people with chronic kidney disease (ckd) and their care partners make healthy lifestyle changes. the main questions this study will answer are: * does ddep help protect kidney function? * does ddep support healthier daily habits? researchers will compare two groups: * one group will receive the ddep and get usual medical care. * the other group will get usual medical care only. participants will: * receive usual care with or without ddep for six months. * visit the clinic at the start and end of the study for health checks and tests. * practice healthy habits at home with or without help from ddep. this study aims to show if adding ddep to regular care can make it easier for people with ckd and their care partners to live healthier lives.

this randomized controlled trial (rct) aims to evaluate the long-term effects of the digital dyadic empowerment program (ddep) in comparison to routine care for people with chronic kidney disease (ckd) and their significant others. the study will assess whether the ddep can improve health outcomes such as kidney function, health-promoting lifestyle behaviors, and the quality of relationships between significant others over a six-month period. the trial will follow the consolidated standards of reporting trials (consort) 2010 and consort-ehealth guidelines to ensure rigorous reporting and transparency. baseline assessments will occur in a private clinic room and will include demographic information, disease-related characteristics, and self-reported measures. participants in both groups will also complete the trans-theoretical model (ttm) staging inventory to evaluate their readiness for lifestyle changes. dyads assigned to the intervention group will receive ddep setup instructions and training on platform use during the baseline visit. throughout the study, dyads will be encouraged to utilize the platform for self-management tasks at home, including diet tracking, exercise planning, and monitoring blood pressure.

Eligibility criteria:
inclusion criteria: 1. the patient has a diagnosis of chronic kidney disease for at least six months; 2. the patient can identify a helpful significant other, and both parties are willing to participate; 3. the patient can communicate in mandarin or taiwanese. exclusion criteria: 1. the significant other is a healthcare provider; 2. the patient or the significant other has a mental illness diagnosis; 3. the patient is currently receiving renal replacement therapies; 4. neither the patient nor the significant other uses a smartphone or the line messaging app.

Keywords: digital health dyadic empowerment healthy lifestyle
the relation between mir-125b-5p and staging of endometriosis

Conditions: Endometriosis

Summary: 78 endometriosis patients presented with infertility were clinically examined and the diagnosis was assured by us imaging. the study also included 11 control fertile women free of gynecological problems as a control for lab tests. patients and controls gave blood samples for lab investigations. all patients underwent diagnostic abdominal laparoscopy under general anesthesia for disease staging. quantitative determination of expression levels of genes of microrna-125b-5p and 203a was conducted using qrt-pcr.


Eligibility criteria:
inclusion criteria: * patients who presented clinical pictures suggestive of em disease exclusion criteria: * patients with previous pelvic or abdominal surgery that may hinder the laparoscopic examination, * patients who were suspicious of having malignancy elsewhere in the body region, * pregnant women, * patients who had diabetes mellitus, * body mass index (bmi) of \>30 kg/m2, coagulopathies, and autoimmune disorders.
effect of ketamine versus sevoflurane on the right ventricular pressure

Conditions: Congenital Pulmonary Stenosis

Summary: the aim of this study is to compare the effect of different anesthetic drugs used for induction of anesthesia ketamine versus sevoflurane on the rv pressure in pediatrics undergoing balloon dilatation for congenital pulmonary stenosis.

critical pulmonary stenosis (ps) is a life-threatening congenital heart disease which manifest during the neonatal period with cyanosis. surgical valvotomy was the procedure of choice for critical ps; however, balloon pulmonary valvoplasty (bpv) has now become the standard management. ketamine is often used for procedural sedation or as adjunct agent for general anesthesia in pediatrics with congenital heart disease. ketamine is a chemical derivative of phencyclidine acting as a selective antagonist of the n-methyl-d-aspartate (nmda) receptor, an ionotropic glutamate receptor that participates in analgesia, amnesia, and sedation pathways. ketamine has minimal impact on hemodynamics in children with congenital heart disease when used at usual clinical doses. systemic vascular resistance and pulmonary vascular resistance are not significantly altered. sevoflurane is a sweet-smelling, highly fluorinated methyl isopropyl ether used as an inhalational anesthetic for induction and maintenance of general anesthesia. it proved to be safe as induction agent in noncardiac surgery and cardiac surgery. sevoflurane has low solubility in blood, produces less arrhythmias and decrease in contractility less than halothane without changing pulmonary to systemic blood flow ratio in pediatrics with congenital heart disease.

Eligibility criteria:
inclusion criteria: 1. age from 1 month to 1 year. 2. both gender 3. isolated congenital pulmonary stenosis exclusion criteria: 1. multiple cardiac congenital anomalies. 2. previous open-heart surgery. 3. other non-cardiac congenital anomalies 4. refusal of parents
strongyloides stercoralis public health control in rwanda

Conditions: Strongyloides Stercoralis Infection; Strongyloides

Summary: the world health organization (who) recently issued guideline for the public health control of strongyloides stercoralis in endemic areas. we aimed to evaluate the feasibility of implementing the who recommendations in rwanda, specifically to intergrate the activities for the public health control of strongyloidiasis in the ongoing national programme for the control of the other soil-transmitted helminths and schistosomiasis, that has been in place for several years. as additional objective, we aimed to estimate the prevalence of s. stercoralis in two districts of rwanda (gisagara and rubavu). to evaluate the feasibility, we asked lab technicians to evaluate challenges emerged during the implementation of the laboratory procedures with a structured questionnaire. also, we evaluated the costs needed to perform these tests. we estimated the prevalence of s. stercoralis by calculating the number of positive cases out of all people tested. the lab technicians participated to a training session, where they were taught the s. stercoralis-specific lab techniques, and to a two-day pilot study where they could practice. the tests used were parasitological techniques (agar stool culture, (apc) and baermann method) and an antibody rapid diagnostic test (rdt). duration of training, with a specific focus on larvae differentiation, was identified as pivotal for a successful implementation of the parasitological techniques. the use of the rdt was instead considered easy to apply at all evaluation time points. raw cost (i.e. not including staff salaries and transport costs) of materials and equipment was below 2 euros/test for each assay. in both districts, strongyloides prevalence was below the threshold recommended by the who for the implementation of mass treatment, hence this aspect was not evaluated.


Eligibility criteria:
inclusion criteria: * people living in the selected districts and households * obtainment of written informed consent (for children's participation, consent was sought from parents/guardians). exclusion criteria: * inability to supply an adequate stool sample
direct and indirect benefits of influenza vaccination in schools and households

Conditions: Influenza Virus Infection; Influenza-like Illness; Acute Respiratory Infection

Summary: the purpose of this study is to determine the degree of indirect benefits to family members and classmates resulting from administration of influenza vaccine to children.


Eligibility criteria:
inclusion criteria: * hong kong residents aged between 7 and 11 and their family members. exclusion criteria: * children with history of hypersensitivity to eggs, egg proteins, gentamicin, gelatin, or arginine or with life-threatening reactions to previous influenza vaccinations. * children receiving aspirin therapy or aspirin-containing therapy. * children with asthma or active wheezing. * children or family members with underlying immunocompromised condition or receiving immunosuppressive agents.
combination chemotherapy followed by alemtuzumab in treating patients with chronic lymphocytic leukemia or prolymphocytic leukemia

Conditions: Prolymphocytic Leukemia

Summary: rationale: drugs used in chemotherapy, such as fludarabine, cyclophosphamide, and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. giving more than one drug (combination chemotherapy) may kill more cancer cells. monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. some block the ability of cancer cells to grow and spread. others can find cancer cells and help kill them or carry cancer-killing substances to them. combination chemotherapy followed by alemtuzumab may be effective in treating chronic lymphocytic leukemia and prolymphocytic leukemia. purpose: this phase ii trial is studying how well giving combination chemotherapy followed by alemtuzumab works in treating patients with t-cell chronic lymphocytic leukemia or prolymphocytic leukemia.

objectives: primary * determine the number of severe adverse events and life-threatening infections in patients with t-cell chronic lymphocytic leukemia or t-cell prolymphocytic leukemia treated with induction chemotherapy comprising fludarabine, cyclophosphamide, and mitoxantrone hydrochloride followed by consolidation therapy comprising alemtuzumab. * determine the remission rate in patients treated with this regimen. secondary * determine the overall and progression-free survival of patients treated with this regimen. * determine the quality of remission in patients treated with this regimen. outline: this is a multicenter study. patients receive induction chemotherapy comprising fludarabine iv and cyclophosphamide iv for 3 days and mitoxantrone hydrochloride iv on 1 day. treatment repeats every 28 days for up to 4 courses. patients then receive consolidation therapy comprising alemtuzumab iv 3 times in week 1 and then weekly for up to 11 weeks. projected accrual: a total of 17 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of t-cell chronic lymphocytic leukemia (t-cll) or t-cell prolymphocytic leukemia (t-pll) * previously untreated disease or patient may have received up to 2 therapies patient characteristics: * ecog performance status 0-2 * life expectancy \> 6 months * no severe organ dysfunction * no other concurrent or previous neoplasm * no autoimmune hemolytic anemia or thrombocytopenia prior concurrent therapy: * see disease characteristics * no prior fludarabine, mitoxantrone hydrochloride, cyclophosphamide, or alemtuzumab

Keywords: prolymphocytic leukemia refractory chronic lymphocytic leukemia stage i chronic lymphocytic leukemia stage ii chronic lymphocytic leukemia stage iii chronic lymphocytic leukemia stage iv chronic lymphocytic leukemia t-cell large granular lymphocyte leukemia
transnasal induction of normothermia for neurogenic fever

Conditions: Stroke, Ischemic; Stroke Hemorrhagic; Seizures; Metabolic Encephalopathy

Summary: the objective of this study is to evaluate the efficacy of the coolstat® transnasal thermal regulating device in reducing temperature in a population of febrile subjects who meet the inclusion/exclusion criteria.


Eligibility criteria:
inclusion criteria: 1. admitted to an intensive care unit for a planned stay of at least 24 hours with a diagnosis of ischemic or hemorrhagic stroke, seizure, or metabolic encephalopathy. 2. ages 18-85 years, inclusive. 3. patient has fever ≥ 38.3°c and ≤ 38.9°c at the time of treatment initiation. 4. patient is orally intubated or has tracheostomy tube and is mechanically ventilated. 5. glasgow coma scale score of 3-11, inclusive. 6. must have informed consent from the patient or the legally authorized representative (lar) making decisions for the patient. exclusion criteria: 1. intubation is contraindicated. 2. weight of ≤ 100lb or ≥ 250lb. 3. active/ongoing epistaxis. 4. known or suspected pregnancy. 5. participation in another ongoing investigational study. 6. prisoners and/or patients for whom no lar is available. 7. patient is in airborne/droplet disease isolation protocol. 8. patient is or suspected to be immunocompromised. 9. nasal septal deviations (per standard of care ct scan; any degree). 10. chronic rhinosinusitis. 11. traumatic brain injury. 12. prior skull-base surgery. 13. penetrating cranial trauma. 14. recent nasal trauma or anterior base skull fracture. 15. any condition for which transnasal air flow would be contraindicated. 16. refractory hypoxemia (partial pressure of oxygen in arterial blood (pao2) below 60 torr or oxyhemoglobin saturation below 90% despite endotracheal intubation, mechanical ventilation, and provision of supplemental oxygen of up to 0.60). 17. refractory hypercarbia (partial pressure of carbon dioxide in arterial blood (paco2) above 50 torr despite endotracheal intubation and conventional mechanical ventilation).

Keywords: shivering, fever, normothermia, ttm
a trial investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of nnc0148-0000-0362 in healthy subjects

Conditions: Diabetes; Diabetes Mellitus, Type 2; Healthy

Summary: this trial is conducted in europe. the aim of this trial is to investigate the safety, tolerability, pharmacokinetics (exposure of drug) and pharmacodynamics (effect of drug) of nnc 0148-0000-0362 as tablets in healthy volunteers. the trial consists of two parts. in part 1, single escalating doses of nnc 0148-0000-0362, placebo or insulin glargine is given. in part 2, subjects will receive single doses of nnc 0148-0000-0362 administered orally or intravenously.


Eligibility criteria:
inclusion criteria: * body mass index 18-28 kg/m\^2 (both inclusive) * subject who is considered to be healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ecg) and clinical laboratory tests performed during the screening visit, as judged by the investigator exclusion criteria: * known or suspected hypersensitivity to trial products or related products * previous participation in this trial. participation is defined as randomised * presence of clinically significant acute gastrointestinal symptoms (e.g. nausea, vomiting, heartburn or diarrhoea) within 2 weeks prior to dosing, as judged by the investigator * any chronic disorder or severe disease which, in the opinion of the investigator, might jeopardise subject's safety or compliance with the protocol
study of gefapixant (mk-7264) in adult japanese participants with unexplained or refractory chronic cough (mk-7264-033)

Conditions: Chronic Cough

Summary: this estimation study (no hypotheses) will evaluate the safety, tolerability, and efficacy of gefapixant (mk-7264) in japanese adult participants with unexplained or refractory chronic cough.


Eligibility criteria:
inclusion criteria: * chest radiograph or computed tomography scan of the thorax (within 5 years of screening/visit 1 and after the onset of chronic cough) not demonstrating any abnormality considered to be significantly contributing to the chronic cough or any other clinically significant lung disease in the opinion of the principal investigator or the sub-investigator. * has had chronic cough for ≥ 1 year and a diagnosis of refractory chronic cough or unexplained chronic cough. * for female participants, is a female who is not pregnant, not breastfeeding, not of childbearing potential, or agrees to follow contraceptive guidance * provides written informed consent and is willing and able to comply with the study protocol (including use of the digital cough recording device and completion of study questionnaires) exclusion criteria: * is a current smoker or has given up smoking within 12 months of screening, or is a former smoker with a pack-year history \>20 pack-years * has a history of upper or lower respiratory tract infection or recent clinically significant change in pulmonary status * has a history of chronic bronchitis * is currently taking an angiotensin converting enzyme inhibitor (acei), or has used an acei within 3 months of screening * has a history of malignancy ≤5 years * has a screening systolic blood pressure \>160 millimeters of mercury (mmhg) or a diastolic blood pressure \>90 mm hg * has a history of cutaneous adverse drug reaction to sulfonamides with or without systemic symptoms or history of anaphylaxis to sulfonamides * is a user of recreational or illicit drugs or has had a recent history of drug or alcohol abuse or dependence * has a known allergy/sensitivity or contraindication to gefapixant * has donated or lost ≥1 unit of blood within 8 weeks prior to the first dose of gefapixant * has previously received gefapixant or is currently participating in or has participated in an interventional clinical study
transdiagnostic group treatments for patients with common mental disorders in primary health care

Conditions: Anxiety Disorders; Depressive Disorders; Stress Disorders

Summary: the purpose of this study is to compare the effects of cbt and mmi on the quality of life and relief of psychological symptoms of patients with common mental disorders or problems attending primary health care centre.

design: clinical randomised non blinded controlled trial. setting: the study was performed in an outpatient primary health care centre serving 36 000 inhabitants. participants: patients (n=278), aged 18-65 years, with common mental problems or disorders were referred to the study by the gps and 245 were included in the study. interventions: participants were randomised to cau or one of two group interventions in addition to cau. these were: a) group cognitive behavioural based therapy (cbt) administered by psychologists once a week for 12 weeks, and b) group multimodal intervention (mmi) based on a protocol comprising a mix of existing group interventions and exercises borrowed from multiple techniques and therapeutic schools and administered by assistant nurses with brief training, including two sessions per week for 6 weeks. main outcome measures: primary outcome measure was the mental component summary score of sf-36. secondary outcome measures were perceived stress scale (pss) and self-rating scale for affective syndromes (cprs-s-a)

Eligibility criteria:
inclusion criteria: * patients with common mental disorders or problems exclusion criteria: patients were excluded if: * they met diagnostic criteria for bipolar or psychotic disorder or severe personality disorder, * were judged to be at risk of committing suicidal acts, and * if they had undergone mmi earlier. the investigators paid no consideration to whether patients were treated with ssri medication.

Keywords: primary health care,common mental disorders, group therapy
the role of small intestinal endocrine cells in type 2 diabetic hyperglucagonemia

Conditions: Type 2 Diabetes

Summary: the purpose of this study is to determine whether excessive secretion of glucagon in type 2 diabetes originates from the pancreatic alpha-cells or endocrine cells in the mucosa of the small intestinal.

hyperglucagonemia contributes significantly to the hyperglycemia characterizing patients with type 2 diabetes. fasting hyperglucagonemia induces hepatic glucose release resulting in elevated fasting levels of plasma glucose. furthermore, lack of postprandial suppression of glucagon secretion - exchanged for a paradoxical postprandial hypersecretion of glucagon - results in increased levels of postprandial plasma glucose. additionally, type 2 diabetes is characterized by decreased postprandial responses of the insulinotropic (and glucagonostatic) peptide hormone glucagon-like peptide-1 (glp-1). recent studies from our group suggest that the intestines are involved in the diminshed suppression of glucagon following ingestion of nutrients. thus, suppression of glucagon during oral glucose ingestion diminishes and reverses to stimulation while suppression during intravenous administered glucose sustains along with development of glucose intolerance. in the small intestines mucosal endocrine l-cells secrete glp-1, which is processed from its precursor, proglucagon, by prohormone convertase 1 (pc1). in the pancreatic alpha-cells proglucagon is processed to glucagon via prohormone convertase 2 (pc2). we plan to examine biopsies from the mucosa of the small intestines from patients with type 2 diabetes and from healthy subjects for glucagon production. furthermore, the volunteers will be subjected to a standard meal test in order to correlate the gene expression studies with the level of postprandial hyperglucagonemia of the subjects.

Eligibility criteria:
inclusion criteria: * diagnosed with type 2 diabetes for at least 3 months * normal hemoglobin * informed consent exclusion criteria: * liver disease (alat/asat \> 2 x normal range) * diabetic nephropathy (se-creatinin \> 130 µm and/or albuminuriu) * treatment with medication that can not be stopped for12 hours
a phase 2 study to evaluate efficacy and safety of vx-561 in subjects aged 18 years and older with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: the purpose of this study is to evaluate the efficacy, safety, pharmacodynamic (pd) and pharmacokinetic (pk) effect of vx-561.


Eligibility criteria:
key inclusion criteria: * must have 1 of the following 9 cftr mutations on at least 1 allele: g551d, g178r, s549n, s549r, g551s, g1244e, s1251n, s1255p, or g1349d * on ivacaftor therapy * fev1 value ≥40% and ≤100% of predicted mean for age, sex, and height key exclusion criteria: * history of clinically significant cirrhosis with or without portal hypertension * history of solid organ or hematological transplantation * lung infection with organisms associated with a more rapid decline in pulmonary status other protocol defined inclusion/exclusion criteria may apply